Bibframe Work

Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis

Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop

Attrition in phase I / Dennis A. Smith and Thomas A. Baillie

Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith

Post-marketing attrition / Dennis A. Smith

Influence of the regulatory environment on attrition / Robert T. Clay

Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt

Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy

Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams

In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis

Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale

Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton